Advertisement
The Journal of Heart and Lung Transplantation
International Society for Heart and Lung Transplantation.

Immune-Checkpoint Inhibitor (ICI) resumption after severe graft injury in a heart transplant recipient with nivolumab-sensitive metastatic melanoma and renal cell carcinoma

Published:September 09, 2022DOI:https://doi.org/10.1016/j.healun.2022.08.004
      While immune-checkpoint inhibitors (ICI) activate the immune system and have transformed cancer therapy, serious immune-related adverse events (irAE) including myocarditis may arise. ICI use in solid organ transplant recipients with cancer carries increased risks of alloreactivity and organ rejection.
      • Johnson DB
      • Balko JM
      • Compton ML
      • et al.
      Fulminant myocarditis with combination immune checkpoint blockade.
      • Saberianfar S
      • Nguyen LS
      • Manouchehri A
      • et al.
      Solid organ transplant rejection associated with immune-checkpoint inhibitors.
      • Nguyen LS
      • Ortuno S
      • Lebrun-Vignes B
      • et al.
      Transplant rejections associated with immune checkpoint inhibitors: A pharmacovigilance study and systematic literature review.
      • Robert C.
      A decade of immune-checkpoint inhibitors in cancer therapy.
      We report a case of a cardiac transplant recipient treated with ICI therapy for 2 ICI sensitive malignancies who developed life-threatening graft injury but resumed successful ICI therapy after augmentation of immunosuppression.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The Journal of Heart and Lung Transplantation
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Johnson DB
        • Balko JM
        • Compton ML
        • et al.
        Fulminant myocarditis with combination immune checkpoint blockade.
        N Engl J Med. 2016; 375: 1749-1755
        • Saberianfar S
        • Nguyen LS
        • Manouchehri A
        • et al.
        Solid organ transplant rejection associated with immune-checkpoint inhibitors.
        Ann Oncol. 2020; 31: 543-544
        • Nguyen LS
        • Ortuno S
        • Lebrun-Vignes B
        • et al.
        Transplant rejections associated with immune checkpoint inhibitors: A pharmacovigilance study and systematic literature review.
        Eur J Cancer. 2021; 148: 36-47
        • Robert C.
        A decade of immune-checkpoint inhibitors in cancer therapy.
        Nat Commun. 2020; 11: 3801
        • Thajudeen A
        • Stecker EC
        • Shehata M
        Arrhythmias after heart transplantation: mechanisms and management.
        J Am Heart Assoc. 2012; 1e001461
        • Palaskas N
        • Lopez-Mattei J
        • Durand JB
        • Iliescu C
        • Deswal A.
        Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment.
        J Am Heart Assoc. 2020; 9e013757
        • Drobni ZD
        • Alvi RM
        • Taron J
        • et al.
        Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque.
        Circulation. 2020; 142: 2299-2311
        • Daud A
        • Mehra MR
        • Siu A
        • et al.
        Immune checkpoint inhibitors in heart or lung transplantation: Early results from a registry initiative.
        J Heart Lung Transplant. 2020; 39: 604-606